



LYRICA[®] Hard Capsules (Pregabalin)

1. NAME OF THE MEDICINAL PRODUCT

LYRICA[®]

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each hard capsule contains 75 mg, 150 mg or 300 mg of pregabalin.

3. PHARMACEUTICAL FORM

Hard capsules.

4. CLINICAL PARTICULARS

4.1. THERAPEUTIC INDICATIONS

Neuropathic pain

Pregabalin is indicated for the treatment of neuropathic pain in adults.^{1,2,3,4,5,6,7,8,9}

Epilepsy

Pregabalin is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalization.^{1,10,11,12}

Generalized Anxiety Disorder

Pregabalin is indicated for the treatment of Generalized Anxiety Disorder (GAD) in adults.¹⁰¹

Fibromyalgia

Pregabalin is indicated for the management of fibromyalgia.¹⁰⁵

4.2. POSOLOGY AND METHOD OF ADMINISTRATION

The dose range is 150 to 600 mg per day given in either two or three divided doses.¹ Pregabalin may be taken with or without food.^{13,14}

Neuropathic pain

Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual patient response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.¹



Fibromyalgia

The usual dose range for most patients is 300 to 450 mg per day given in two divided doses. Some patients may derive additional benefit at 600 mg per day. Dosing should begin at 75 mg two times a day (150 mg per day) and may be increased to 150 mg two times a day (300 mg per day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient benefit with 300 mg per day may be further increased to 225 mg two times a day (450 mg per day). If needed, in some patients, based on individual response and tolerability, the dose may be increased to maximum dosage of 600 mg per day after an additional week.^{105,108}

Epilepsy

Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual patient response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week.¹

Generalized Anxiety Disorder

The dose range is 150 to 600 mg per day given as two or three divided doses. The need for treatment should be reassessed regularly.¹⁰¹

Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual patient response and tolerability, the dosage may be increased to 300 mg per day after 1 week. Following an additional week, the dosage may be increased to 450 mg/day. The maximum dosage of 600 mg per day may be achieved after an additional week.¹⁰¹

Discontinuation of pregabalin

If Pregabalin has to be discontinued; it is recommended this should be done gradually over a minimum of 1 week.

Patients with renal impairment

Dosage reduction in patients with compromised renal function¹⁵ must be individualized according to creatinine clearance (CL_{cr}) (see Section **5.2. Pharmacokinetic Properties, Pharmacokinetics in special patient groups, Renal impairment**), as indicated in Table 1 determined using the following formula:

$$CL_{cr} \text{ (mL/min)} = \frac{[140 - \text{age (years)}] \times \text{weight (kg)} (\times 0.85 \text{ for female patients})}{72 \times \text{serum creatinine (mg/dL)}}$$

For patients receiving hemodialysis¹⁶, the pregabalin daily dose should be adjusted based on renal function. In addition to the daily dose, a supplementary dose should be given immediately following every 4-hour haemodialysis treatment (see Table 1).



Creatinine Clearance (CL _{cr})(mL/min)	Total Pregabalin Daily dose*		Dose Regimen
	Starting dose (mg/day)	Maximum Dose (mg/day)	
≥60	150	600	BID or TID
≥30 - <60	75	300	BID or TID
≥15 - <30	25-50	150	QD or BID
<15	25	75	QD
Supplementary dosage following haemodialysis (mg)			
	25	100	Single dose ⁺

TID = Three divided doses.

BID = Two divided doses.

QD = Single daily dose.

* Total daily dose (mg/day) should be divided as indicated by dose regimen to provide mg/dose.

⁺ Supplementary dose is a single additional dose.

Use in patients with hepatic impairment

No dosage adjustment is required for patients with hepatic impairment (see Section **5.2. Pharmacokinetic Properties**, Pharmacokinetics in special patient groups, Hepatic impairment).

Use in children and adolescents (12 to 17 years of age)

The safety and effectiveness of pregabalin in pediatric patients below the age of 12 years and adolescents has not been established.

The use in children is not recommended (see Section **5.3. Preclinical Safety Data**).

Use in the elderly (over 65 years of age)

Elderly patients may require a dose reduction of pregabalin due to decreased renal function (see Section **5.2. Pharmacokinetic Properties**, Pharmacokinetics in special patient groups, Elderly (over 65 years of age)).

4.3. CONTRAINDICATIONS

Hypersensitivity to the active substance or to any of the excipients.

4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.¹⁷

Some diabetic patients who gain weight on pregabalin treatment may need to adjust hypoglycemic medications.



There have been reports in the postmarketing experience of hypersensitivity reactions, including cases of angioedema. Pregabalin should be discontinued immediately if symptoms of angioedema, such as facial, perioral, or upper airway swelling occur.¹⁰⁷

Pregabalin treatment has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in the elderly population.¹⁸ There have also been postmarketing reports of loss of consciousness, confusion, and mental impairment.^{102,103,104} Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medication.

In the postmarketing experience, transient visual blurring and other changes in visual acuity have been reported in patients treated with pregabalin. Discontinuation of pregabalin may result in resolution or improvement of these visual symptoms.¹⁰⁹

There are insufficient data for the withdrawal of concomitant antiepileptic medicinal products, once seizure control with pregabalin in the add-on situation has been reached, in order to reach monotherapy on pregabalin.

After discontinuation of short-term and long-term treatment with pregabalin, withdrawal symptoms have been observed in some patients. The following events have been mentioned: insomnia, headache, nausea, anxiety, hyperhidrosis and diarrhea.^{95,113,114,115}

Pregabalin is not known to be active at receptor sites associated with drugs of abuse.¹²¹ Cases of misuse, abuse and dependence have been reported in the post-marketing database. As with any CNS active drug, carefully evaluate patients for history of drug abuse and/or psychiatric disorders. Patients should be observed for signs of pregabalin misuse, abuse or dependence (e.g., development of tolerance, dose escalation, drug-seeking behavior).^{122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,142,149}

Although the effects of discontinuation on the reversibility of renal failure have not been systematically studied, improved renal function following discontinuation or dose reduction of pregabalin has been reported.¹⁰²

Although there has been no causal relationship identified between exposure to pregabalin and congestive heart failure, there have been postmarketing reports of congestive heart failure in some patients receiving pregabalin. In short-term trials of patients without clinically significant heart or peripheral vascular disease, there was no apparent association between peripheral edema and cardiovascular complications such as hypertension or congestive heart failure. Because there are limited data on severe congestive heart failure patients, pregabalin should be used with caution in these patients (see Section **4.8. Undesirable Effects**).⁹⁶

Caution is advised when prescribing pregabalin concomitantly with opioids due to risk of CNS depression. In an observational study of opioid users, those patients who took pregabalin concomitantly with an opioid had an increased risk for opioid-related death compared to opioid use alone (adjusted odds ratio [aOR], 1.68 [95% CI, 1.19 to 2.36]).¹⁴²

Women of childbearing potential/Contraception

Pregabalin use in the first trimester of pregnancy may cause major birth defects in the unborn child. Pregabalin should not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the fetus. Women of childbearing potential must use effective contraception during treatment (see Section **4.6. Fertility, Pregnancy and Lactation**).¹⁴⁸



4.5. INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION

Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (<2% of a dose recovered in urine as metabolites),¹⁹ does not inhibit drug metabolism *in vitro*,^{20,21,22} and is not bound to plasma proteins, it is unlikely to produce, or be subject to, pharmacokinetic interactions.

Accordingly, in *in vivo* studies no clinically relevant pharmacokinetic interactions were observed between pregabalin and phenytoin,²³ carbamazepine,²⁴ valproic acid,²⁵ lamotrigine,²⁶ gabapentin,²⁷ lorazepam,²⁸ oxycodone²⁹ or ethanol.³⁰ Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics, insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin clearance.³¹

Co-administration of pregabalin with the oral contraceptives norethisterone and/or ethinyl estradiol does not influence the steady-state pharmacokinetics of either substance.³² Pregabalin may potentiate the effects of ethanol and lorazepam.¹⁰² In controlled clinical trials, multiple oral doses of pregabalin co-administered with oxycodone²⁹, lorazepam²⁸, or ethanol³⁰ did not result in clinically important effects on respiration. Pregabalin appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone.²⁹

In the postmarketing experience, there are reports of respiratory failure, coma and deaths in patients taking pregabalin and other CNS depressant medications, including in patients who are substance abusers.^{102,145} There are post-marketing reports of events related to reduced lower gastrointestinal tract function (e.g., intestinal obstruction, paralytic ileus, constipation) when pregabalin was co-administered with medications that have the potential to produce constipation, such as opioid analgesics.^{113,114}

No specific pharmacodynamic interaction studies were conducted in elderly volunteers.

4.6. FERTILITY, PREGNANCY AND LACTATION

Pregnancy

There is a limited amount of¹⁴⁷ data on the use of pregabalin in pregnant women.

Data from an observational study, which included more than 2,700 pregnancies exposed to pregabalin based on routinely collected data from administrative and medical registers in Denmark, Finland, Norway, and Sweden, do not suggest substantially increased risks of major congenital malformations, adverse birth outcomes, or abnormal postnatal neurodevelopmental outcomes in pregabalin-exposed pregnancies.¹⁴⁷

Major congenital malformations

The adjusted prevalence ratios (aPRs) and 95% confidence intervals (CI) in the standard meta-analysis for first-trimester pregabalin monotherapy-exposed vs. unexposed to anti-epileptic drugs was **1.14 (0.96-1.35)**.

Birth and postnatal neurodevelopmental outcomes

There were no statistically significant findings for stillbirth, low birth weight, preterm birth, small for gestational age, low Apgar score, and microcephaly.



In pediatric population exposed *in utero*, the study did not provide evidence of an increased risk for attention deficit hyperactivity disorder (ADHD), autism spectrum disorders (ASD), and intellectual disabilities.¹⁴⁷

Studies in animals have shown reproductive toxicity (see Section 5.3. **Preclinical Safety Data**).^{33,34,35,36,37,38} Pregabalin should not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the fetus. Effective contraception must be used in women of childbearing potential.

Lactation

Pregabalin is excreted in the milk of lactating women (see Section 5.2. **Pharmacokinetic Properties**).¹⁴³ As the safety of pregabalin in infants is not known, breast-feeding is not recommended during treatment with pregabalin. A decision must be made whether to discontinue breast feeding or to discontinue from pregabalin therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

4.7. EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

Pregabalin may cause dizziness and somnolence and therefore may influence the ability to drive or use machines.^{18,28,29,30,40} Patients are advised not to drive, operate complex machinery or engage in other potentially hazardous activities until it is known whether this medication affects their ability to perform these activities.

4.8. UNDESIRABLE EFFECTS

The pregabalin clinical program involved over 12,000 patients who were exposed to pregabalin, of whom over 7,000 were in double-blind placebo-controlled trials. The most commonly reported adverse reactions were dizziness and somnolence. Adverse reactions were usually mild to moderate in intensity. In all controlled studies, the discontinuation rate due to adverse reactions was 14% for patients receiving pregabalin and 5% for patients receiving placebo.¹¹² The most common adverse reactions resulting in discontinuation from pregabalin treatment groups were dizziness and somnolence.¹⁸

Selected adverse drug reactions that were treatment related in the pooled analysis of clinical trials are listed in the table below by System Organ Class (SOC). The frequency of these terms has been based on all-causality adverse drug reactions in the clinical trial data set (very common ($\geq 1/10$), common ($\geq 1/100$, $< 1/10$), uncommon ($\geq 1/1000$, $< 1/100$) and rare ($< 1/1000$)).^{18,108,111,141}

The adverse reactions listed may also be associated with the underlying disease and/or concomitant medications.¹⁸

Table 2. Adverse Drug Reactions from Clinical Trial Experience

System Organ Class	Adverse drug reactions
Infections and Infestations	
Common	Nasopharyngitis
Blood and lymphatic system disorders	
Uncommon	Neutropenia
Metabolism and nutrition disorders	
Common	Appetite increased
Uncommon	Anorexia, hypoglycemia
Psychiatric disorders	



System Organ Class	Adverse drug reactions
Common	Euphoric mood, confusion, irritability, depression, disorientation, insomnia, libido decreased
Uncommon	Hallucination, restlessness, agitation, depressed mood, elevated mood, mood swings, depersonalization, abnormal dreams, word finding difficulty, libido increased, anorgasmia
Rare	Panic attack, disinhibition, apathy
Nervous system disorders	
Very Common	Dizziness, somnolence
Common	Ataxia, coordination abnormal, tremor, dysarthria, amnesia, memory impairment, disturbance in attention, paraesthesia, hypoesthesia, sedation, balance disorder, lethargy
Uncommon	Syncope, myoclonus, psychomotor hyperactivity, dyskinesia, dizziness postural, intention tremor, nystagmus, cognitive disorder, speech disorder, hyporeflexia, hyperaesthesia, burning sensation
Rare	Stupor, parosmia, hypokinesia, ageusia, dysgraphia
Eye disorders	
Common	Vision blurred, diplopia
Uncommon	Peripheral vision loss, visual disturbance, eye swelling, visual field defect, visual acuity reduced, eye pain, asthenopia, photopsia, dry eye, lacrimation increased, eye irritation
Rare	Oscillopsia, altered visual depth perception, mydriasis, strabismus, visual brightness
Ear and labyrinth disorders	
Common	Vertigo
Uncommon	Hyperacusis
Cardiac disorders	
Uncommon	Tachycardia, atrioventricular block first degree, sinus bradycardia
Rare	Sinus tachycardia, sinus arrhythmia
Vascular disorders	
Uncommon	Hypotension, hypertension, hot flushes, flushing, peripheral coldness
Respiratory, thoracic and mediastinal disorders	
Uncommon	Dyspnoea, epistaxis, cough, nasal congestion, rhinitis, snoring
Rare	Throat tightness, nasal dryness
Gastrointestinal disorders	
Common	Vomiting, constipation, flatulence, abdominal distension, dry mouth
Uncommon	Gastroesophageal reflux disease, salivary hypersecretion, hypoesthesia oral
Rare	Ascites, pancreatitis, dysphagia
Skin and subcutaneous tissue disorders	
Uncommon	Rash papular, urticaria, sweating
Rare	Cold sweat
Musculoskeletal and connective tissue disorders	
Common	Muscle cramp, arthralgia, back pain, pain in limb, cervical spasm
Uncommon	Joint swelling, myalgia, muscle twitching, neck pain, muscle stiffness
Rare	Rhabdomyolysis
Renal and urinary disorders	
Uncommon	Urinary incontinence, dysuria
Rare	Renal failure, oliguria
Reproductive system and breast disorders	
Uncommon	Erectile dysfunction, sexual dysfunction, ejaculation delayed, dysmenorrhoea



System Organ Class	Adverse drug reactions
Rare	Breast pain, amenorrhea, breast discharge, breast enlargement ¹²⁰
General disorders and administration site conditions	
Common	Oedema peripheral, oedema, gait abnormal, fall, feeling drunk, feeling abnormal, fatigue
Uncommon	Generalised oedema, chest tightness, pain, pyrexia, thirst, chills, asthenia
Investigations	
Common	Weight increased
Uncommon	Blood creatine phosphokinase increased, alanine aminotransferase increased, aspartate aminotransferase increased, blood glucose increased, platelet count decreased, blood potassium decreased, weight decreased
Rare	White blood cell count decreased, blood creatinine increased

The following adverse drug reactions were reported during POST-MARKETING SURVEILLANCE:

Immune system disorder: Uncommon¹⁴¹: Hypersensitivity⁹⁷; Rare¹⁴¹: Angioedema¹⁰⁷, allergic reaction⁹⁷

Nervous system disorders: Very Common¹⁴¹: Headache⁹³; Uncommon: Loss of consciousness^{102,103}, mental impairment^{102,104}

Eye disorders: Rare¹⁴¹: Keratitis^{109, §}

Cardiac disorders: Rare¹⁴¹: Congestive heart failure⁹⁶

Respiratory, thoracic and mediastinal disorders: Rare¹⁴¹: Pulmonary oedema^{110, §}

Gastrointestinal disorders: Common¹⁴¹: Nausea⁹⁴, diarrhoea⁹⁸; Rare¹⁴¹: Swollen tongue^{91,92}

Skin and subcutaneous tissue disorders: Uncommon¹⁴¹: Face swelling^{91,92}, pruritus⁹⁹, Rare: Stevens-Johnson syndrome¹⁵⁰

Renal and urinary disorders: Rare¹⁴¹: Urinary retention¹⁰⁶

Reproductive system and breast disorders: Rare¹⁴¹: Gynaecomastia^{120, §}

General disorders and administration site conditions: Uncommon¹⁴¹: Malaise^{113,114}

§ Adverse drug reaction frequency estimated using “The Rule of 3”¹⁴¹

4.9. OVERDOSE

In overdoses up to 15 g, no unexpected adverse reactions were reported.¹⁸

In the postmarketing experience, the most commonly reported adverse events observed when pregabalin was taken in overdose included affective disorder, somnolence, confusional state, depression, agitation, and restlessness.¹⁰² Seizures were also reported.¹⁴⁴

Treatment of pregabalin overdose should include general supportive measures and may include haemodialysis if necessary (see Section 4.2. Posology and Method of Administration, Table 1).



5. PHARMACOLOGICAL PROPERTIES

5.1. PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: Antiepileptics, ATC code: N03A (proposed)

The active substance, pregabalin, is a gamma-aminobutyric acid analogue ((S)-3-(aminomethyl)-5-methylhexanoic acid).

Mechanism of action

Pregabalin binds to an auxiliary subunit ($\alpha_2\text{-}\delta$ protein) of voltage-gated calcium channels in the central nervous system.^{41,42,43}

Evidence from animal models with nerve damage has shown that pregabalin reduces calcium dependent release of pronociceptive neurotransmitters in the spinal cord possibly by disrupting calcium trafficking and/or reducing calcium currents.¹¹⁶ Evidence from other animal models of nerve damage suggest the antinociceptive activities of pregabalin may also be mediated through interactions with the descending noradrenergic and serotonergic pathways.^{117,118,119}

Clinical experience

Neuropathic pain

Efficacy has been shown in studies in diabetic neuropathy^{1,2,3,4,5,6} and postherpetic neuralgia.^{7,8,9} Efficacy has not been studied in other models of neuropathic pain.

Pregabalin has been studied in 9 controlled clinical studies of up to 13 weeks with twice a day dosing and up to 8 weeks with three times a day dosing. Overall, the safety and efficacy profiles for twice a day and three times a day dosing regimens were similar.

In clinical trials up to 13 weeks, a reduction in pain was seen by Week 1 and was maintained throughout the treatment period.

In controlled clinical trials 35% of the pregabalin treated patients and 18% of the patients on placebo had a 50% improvement in pain score. For patients not experiencing somnolence, such an improvement was observed in 33% of patients treated with pregabalin and 18% of patients on placebo. For patients who experienced somnolence the responder rates were 48% on pregabalin and 16% on placebo.

Fibromyalgia

Pregabalin as monotherapy has been studied in 5 placebo-controlled studies, three of 12 weeks fixed-dose duration, one of 7 weeks fixed-dose duration and a 6-month study demonstrating long-term efficacy. Pregabalin treatment in all fixed dose studies produced a significant reduction in pain associated with fibromyalgia at doses from 300 to 600 mg/day (BID).

In the three 12-week fixed-dose studies, 40% of pregabalin-treated patients experienced a 30% or more improvement in pain score versus 28% of the patients on placebo; 23% of treated patients experienced a 50% or more improvement in pain score versus 15% of the patients on placebo.



Pregabalin produced significantly superior global assessment scores via the Patient Global Impression of Change (PGIC) in the three 12-week fixed-dose studies as compared to placebo treatment. (41% patients feeling very much or much improved on pregabalin versus 29% on placebo). As measured by Fibromyalgia Impact Questionnaire (FIQ), pregabalin produced a statistically significant improvement in function versus placebo treatment in 2 out of the 3 fixed-dose studies in which it was evaluated.

Pregabalin treatment produced significant improvements in patient-reported sleep outcomes in the 4-fixed dose studies as measured by Medical Outcomes Study Sleep Scale (MOS-SS) Sleep disturbance subscale, MOS-SS overall sleep problem index, and the daily sleep quality diary.

In the 6-month study, improvement in pain, global assessment (PGIC), function (FIQ total score) and sleep (MOS-SS Sleep disturbance subscale) were maintained for pregabalin-treated patients for a significantly longer period compared to placebo.

Pregabalin 600 mg/day showed an additional improvement in patient-reported sleep outcomes as compared to 300 and 450 mg/day; mean effects on pain, global assessment, and FIQ were similar at 450 and 600 mg/day, although the 600 mg/day dose was less well tolerated.¹⁰⁸

Epilepsy

Pregabalin has been studied in 3 controlled clinical studies of 12-week duration with either twice a day dosing or three times a day dosing.^{1,10,11,12} Overall, the safety and efficacy profiles for twice a day and three times a day dosing regimens were similar.

A reduction in seizure frequency was observed by Week 1.

Generalized Anxiety Disorder

Pregabalin has been studied in 6 controlled studies of 4 to 6 weeks duration, an elderly study of 8 weeks duration and a long-term relapse prevention study with a double-blind relapse prevention phase of 6 months duration.¹⁰¹

Relief of the symptoms of GAD as reflected by the Hamilton Anxiety Rating Scale (HAM-A) was observed by Week 1.¹⁰¹

In controlled clinical trials (4-8 weeks duration), 52% of the pregabalin-treated patients and 38% of the patients on placebo had at least a 50% improvement in HAM-A total score from baseline to endpoint.

5.2. PHARMACOKINETIC PROPERTIES

Pregabalin steady-state pharmacokinetics are similar in healthy volunteers, patients with epilepsy receiving anti-epileptic drugs and patients with chronic pain.^{44,45}



Absorption

Pregabalin is rapidly absorbed when administered in the fasted state, with peak plasma concentrations occurring within 1 hour following both single and multiple dose administration. Pregabalin oral bioavailability is estimated to be $\geq 90\%$ and is independent of dose.⁴⁶ Following repeated administration, steady state is achieved within 24 to 48 hours. The rate of pregabalin absorption is decreased when given with food resulting in a decrease in C_{\max} by approximately 25-30% and a delay in t_{\max} to approximately 2.5 hours. However, administration of pregabalin with food has no clinically significant effect on the extent of pregabalin absorption.^{13,14}

Distribution

In preclinical studies, pregabalin has been shown to cross the blood brain barrier in mice, rats, and monkeys.^{47,48,49,50} Pregabalin has been shown to cross the placenta in rats and is present in the milk of lactating rats.³⁹ In humans, the apparent volume of distribution of pregabalin following oral administration is approximately 0.56 L/kg. Pregabalin is not bound to plasma proteins.

Metabolism

Pregabalin undergoes negligible metabolism in humans. Following a dose of radiolabelled pregabalin, approximately 98% of the radioactivity recovered in the urine was unchanged pregabalin. The N-methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose.¹⁹ In preclinical studies, there was no indication of racemisation of pregabalin S-enantiomer to the R-enantiomer.

Elimination

Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug.¹⁵

Pregabalin mean elimination half-life is 6.3 hours.⁴⁶ Pregabalin plasma clearance and renal clearance are directly proportional to creatinine clearance (see Section **5.2. Pharmacokinetic Properties, Pharmacokinetics in special patient groups, Renal impairment**).¹⁵

Dosage adjustment in patients with reduced renal function or undergoing hemodialysis is necessary (see Section **4.2. Posology and Method of Administration, Table 1**).¹⁵

Linearity/non-linearity

Pregabalin pharmacokinetics are linear over the recommended daily dose range.⁴⁶ Inter-subject pharmacokinetic variability for pregabalin is low (<20%). Multiple dose pharmacokinetics are predictable from single-dose data. Therefore, there is no need for routine monitoring of plasma concentrations of pregabalin.

Pharmacokinetics in special patient groups

Gender

Clinical trials indicate that gender does not have a clinically significant influence on the plasma concentrations of pregabalin.



Renal impairment

Pregabalin clearance is directly proportional to creatinine clearance.¹⁵ In addition, pregabalin is effectively removed from plasma by hemodialysis (following a 4-hour hemodialysis treatment plasma pregabalin concentrations are reduced by approximately 50%).¹⁶ Because renal elimination is the major elimination pathway, dosage reduction in patients with renal impairment and dosage supplementation following hemodialysis is necessary (see Section **4.2. Posology and Method of Administration**, Table 1).^{15,16,19}

Hepatic impairment

No specific pharmacokinetic studies were carried out in patients with impaired liver function. Since pregabalin does not undergo significant metabolism and is excreted predominantly as unchanged drug in the urine, impaired liver function would not be expected to significantly alter pregabalin plasma concentrations.¹⁹

Elderly (over 65 years of age)

Pregabalin clearance tends to decrease with increasing age. This decrease in pregabalin oral clearance is consistent with decreases in creatinine clearance associated with increasing age. Reduction of pregabalin dose may be required in patients who have age-related compromised renal function (see Section **4.2. Posology and Method of Administration** Table 1).¹⁵

Breast-feeding mothers

The pharmacokinetics of 150 mg pregabalin given every 12 hours (300 mg daily dose) was evaluated in 10 lactating women who were at least 12 weeks postpartum. Lactation had little to no influence on pregabalin pharmacokinetics. Pregabalin was excreted into breast milk with average steady state concentrations approximately 76% of those in maternal plasma. The estimated average daily infant dose of pregabalin from breast milk (assuming mean milk consumption of 150 mL/kg/day) was 0.31 mg/kg/day, which on a mg/kg basis would be approximately 7% of the maternal dose.¹⁴³

5.3. PRECLINICAL SAFETY DATA

In conventional safety pharmacology studies in animals, pregabalin was well-tolerated at clinically relevant doses. In repeated-dose toxicity studies in rats^{51,52,53,54,55} and monkeys^{56,57,58,59,60,61,62} CNS effects were observed, including hypoactivity, hyperactivity and ataxia. An increased incidence of retinal atrophy commonly observed in aged albino rats was seen after long-term exposure to pregabalin at exposures ≥ 5 times the mean human exposure at the maximum recommended clinical dose.

Teratogenicity

Pregabalin was not teratogenic in mice⁶³, rats^{33,34,35,36,37} or rabbits³⁸. Fetal toxicity in rats and rabbits occurred only at exposures sufficiently above human exposure. In prenatal/postnatal toxicity studies, pregabalin induced offspring developmental toxicity in rats at exposures >2 times the maximum recommended human exposure.^{64,65}

Mutagenicity

Pregabalin is not genotoxic based on results of a battery of *in vitro*^{66,67,68,69,70,71} and *in vivo*^{72,73,74,75} tests.



Carcinogenicity

Two-year carcinogenicity studies with pregabalin were conducted in rats^{76,77,78} and mice.^{79,80,81,82,83} No tumors were observed in rats at exposures up to 24 times the mean human exposure at the maximum recommended clinical dose of 600 mg/day. In mice, no increased incidence of tumors was found at exposures similar to the mean human exposure, but an increased incidence of haemangiosarcoma was observed at higher exposures. The non-genotoxic mechanism of pregabalin-induced tumor formation in mice involves platelet changes and associated endothelial cell proliferation. These platelet changes were not present in rats or in humans based on short-term and limited long-term clinical data. There is no evidence to suggest an associated risk to humans.

In juvenile rats the types of toxicity do not differ qualitatively from those observed in adult rats. However, juvenile rats are more sensitive. At therapeutic exposures, there was evidence of CNS clinical signs of hyperactivity and bruxism and some changes in growth (transient body weight gain suppression). Effects on the estrus cycle were observed at 5-fold the human therapeutic exposure. Neurobehavioral/cognitive effects were observed in juvenile rats 1-2 weeks after exposure >2 times (acoustic startle response) or >5 times (learning/memory) the human therapeutic exposure. Reduced acoustic startle response was observed in juvenile rats 1-2 weeks after exposure at >2 times the human therapeutic exposure. Nine weeks after exposure, this effect was no longer observable.^{84,85,86,87,88,89,90,91,92,93,94,100}

6. PHARMACEUTICAL PARTICULARS

6.1. LIST OF EXCIPIENTS

Capsules Content:

Lactose Monohydrate
Maize Starch
Talc

Capsules Shell:

Gelatin
Titanium Dioxide (E171)
Sodium Laurilsulfate
Silica, Colloidal anhydrous Water

Printing Ink:

Shellac
Black Iron Oxide (E172)
Propylene Glycol
Potassium Hydroxide

6.2. INCOMPATIBILITIES

Not applicable.

6.3. SHELF LIFE

Please see pack for expiry of product.



6.4. SPECIAL PRECAUTIONS FOR STORAGE

Store below 30°C.

Protect from sunlight, heat and moisture.

6.5. NATURE AND CONTENTS OF CONTAINER

LYRICA® Capsules are available in PVC and Aluminum foil packing, blister pack containing 14 capsules.

- 75 mg: White hard capsules with “Pfizer” marked on the cap and “PGN 75” on the body.
- 150 mg: White hard capsules with “Pfizer” marked on the cap and “PGN 150” on the body.
- 300 mg: White and orange hard capsules with “Pfizer” marked on the cap and “PGN 300” on the body.

LYRICA LPD/PK-10

According to CDS V 25 Dated: 15 February 2022; Supersedes CDS V 24 dated: 17 December 2021

Marketed by:

Pfizer Pakistan Limited

Please visit our website www.pfizerpro.com.pk for latest version of Product leaflet.



7. REFERENCES

1. Schauerte M. Summary of Clinical Efficacy Section 2.7.3. RR-REG 720-30233, November 24, 2003.
2. Allen R, Bockbrader H, Daigle S, LaMoreaux L, Sharma U. A Double-Blind Placebo-Controlled Trial of Pregabalin for Treatment of Painful Diabetic Peripheral Neuropathy (Protocol 1008-14). RR 720-04236, October 15, 2001.
3. Allen R, Bockbrader H, Gorospe S, Iacobellis D, LaMoreaux L. A 5-Week, Double-Blind, Placebo-Controlled Trial of 3 Dosages of Pregabalin (75, 300, and 600 mg/day) for Treatment of Patients With Painful Diabetic Peripheral Neuropathy (Protocol 1008-029). RR 720-04242, October 15, 2001.
4. Dougherty K, Maisonobe P, Roder B, Rigaudy L, Versavel M, Vincent E. A Placebo-Controlled Trial of Pregabalin and Amitriptyline for Treatment of Painful Diabetic Peripheral Neuropathy (Protocol 1008-040). RR720-30054, October 9, 2001.
5. Aills M, Glessner C, Iacobellis D, Moore J, Sharma U. An 8-Week, Double-Blind, Placebo-Controlled Trial of Pregabalin (300 mg/day) for Relief of Pain in Patients With Painful Diabetic Peripheral Neuropathy (Protocol 1008-131). RR 720-04452, October 15, 2001.
6. Glessner C, Mathe H, Soudant D, Rowse L *et al.* A 12-Week Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Pregabalin Twice a Day (BID) for Relief of Pain Associated With Diabetic Peripheral Neuropathy (Protocol 1008-149). RR 720-30080, June 14, 2003.
7. Aills M, Allen R, Bockbrader H, Corbin A, LaMoreaux L. A 5-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study of Pregabalin (75 and 150 mg/day) in Patients With Postherpetic Neuralgia (Protocol 1008-030). RR 720-04189, October 15, 2001.
8. Jacquot F, Spiegel K, Versavel M, Vincent E. An 8-Week, Double-Blind, Placebo-Controlled, Parallel Group Study of Pregabalin (150 and 300 mg/day) in Patients With Postherpetic Neuralgia (Protocol 1008-045). RR 720-04356, June 10, 2004.
9. Bockbrader H, Corbin A, Foster J, LaMareaux L, Remmers A, Young J. An 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study of Pregabalin in Patients With Postherpetic Neuralgia (Protocol 1008-127). RR 720-04457, June 15, 2004.
10. Bockbrader H, Garofalo E, Greiner M, Henkin S, Knapp L, Smith T. Pregabalin BID/TID Add-On Study: A Double-Blind, Placebo-Controlled, Multicenter Study in Patients With Partial Seizures (Protocol 1008-009). RR 720-04094, November 8, 2002.
11. Aills M, Anhut H, Bockbrader H, Colin P, Garofalo E, Knapp L, Mathe H. Pregabalin TID Add-On Trial: A Double-Blind, Placebo-Controlled, Multicenter Study in Patients With Partial Seizures (Protocol 1008-011). RR 720-04098, June 8, 2004.
12. Bockbrader H, Garofalo E, Knapp L, Kugler A, Laughlin K, Robbins J. Pregabalin BID Add-On Trial: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study in Patients With Partial Seizures (Protocol 1008-034). RR 720-04102, November 22, 2002.



13. Alvey C, Bockbrader H, Corrigan B, Posvar E, Radulovic L. A Single-Dose Food Effect and Relative Bioavailability Study of CI-1008 Capsule and Solution Doses in Healthy Volunteers (Protocol 1008-003). RR 744-00386, August 2, 2000.
14. Alvey C, Posvar E, Randinitis E, Wesche D. A Single-Dose Study to Assess the Effect of Food on the Pharmacokinetics of CI-1008 Market-Image Capsules in Healthy Volunteers (Protocol 1008-128-0). RR 744-00521, April 10, 2000.
15. Alvey C, Randinitis E, Posvar E. An Oral, Single-Dose Pharmacokinetic Study of Pregabalin (CI-1008) in Subjects With Various Degrees of Renal Function (Protocol 1008-049-0). RR 744-00575, September 8, 2000.
16. Alvey C, Bockbrader H, Posvar E, Randinitis E. An Oral, Single-Dose Pharmacokinetic Study of Pregabalin (CI-1008) in Patients on Chronic Hemodialysis (Protocol 1008-121). RR 744-00520, September 14, 2000.
17. Excipients in the Label and Package Leaflet of Medicinal Products for Human Use, Directive 92/27/EEC, June 1997.
18. Carter C. Summary of Clinical Safety, Section 2.7.4. RR-REG 720-30235, November 24, 2003.
19. Alvey C, Bockbrader H, Corrigan B, Pool W, Posvar E. A Study of the Mass Balance and Metabolism of [¹⁴C]CI-1008 (Pregabalin) in Healthy Volunteers (Protocol 1008-005). RR 744-00510, February 24, 2000.
20. Pool W. Characterization of the Inhibitory Profile of Parke-Davis Compound CI-1008, Toward Isoforms of Human Cytochrome P450. RR 764-03016, April 2, 1998.
21. Bauman J, Sinz M, Sahi J, Talaat R. CI-1008: Rat, Dog, Monkey, and Human Hepatocyte Metabolic Profiles. RR 764-03070, November 4, 1998.
22. Sinz M, Radulovic L. CI-1008 *in vitro* Metabolism. RR 764-02235, October 10, 1994.
23. Alvey C, Bockbrader H, Randinitis E, *et al.* A Multiple-Dose Drug Interaction Study of Pregabalin (CI-1008) in Patients With Partial Epilepsy Maintained on Phenytoin Monotherapy (Protocol 1008-140). RR 744-00589, September 18, 2002.
24. Alvey C, Bron N, Hounslow N, O'Connell D, Randinitis E. A Multiple-Dose Drug Interaction Study of Pregabalin (CI-1008) in Patients With Epilepsy Maintained on Carbamazepine (Protocol 1008-019-0). RR 744-00489, September 5, 2000.
25. Alvey C, Bron N, Hounslow N, O'Connell D, Randinitis E, Tahaoglu E. A Multiple-Dose Drug Interaction Study of Pregabalin (CI-1008) in Patients With Epilepsy Maintained on Sodium Valproate (Protocols 1008-018-0 and 1008-127-0). RR 744-00481, September 5, 2000.
26. Alvey C, Bron N, Hounslow N, O'Connell D, Randinitis E, Tahaoglu E. A Multiple-Dose Drug Interaction Study of Pregabalin (CI-1008) in Patients With Epilepsy Maintained on Lamotrigine (Protocol 1008-020). RR 744-00495, August 17, 2000.



27. Alvey C, Posvar E, Randinitis E, Tahaoglu E, Wesche D. A Single-Dose Drug Interaction Study to Determine the Pharmacokinetics of Pregabalin Capsules and Gabapentin Capsules Administered Either Alone or in Combination in Healthy Volunteers (Protocol 1008-077-0). RR 744-00505, July 19, 2000.
28. Abel R, Alvey C, Bron N, Mitchell D, O'Connell D, Randinitis E, Steigerwald E. Evaluation of the Potential Pharmacodynamic Interaction Between Pregabalin and Lorazepam Administered Orally to Healthy Volunteers (Protocol 1008-076-0). RR 744-00546, September 8, 2000.
29. Abel R, Alvey C, Bron N, Mitchell D, Munk B, O'Connell D, Randinitis E. Evaluation of the Potential Pharmacodynamic Interaction Between Pregabalin and Oxycodone Administered Orally to Healthy Volunteers (Protocol 1008-078-0). RR 744-00578, September 8, 2000.
30. Abel R, Alvey C, Bron N, *et al.* A Double-Blind Crossover Study to Evaluate the Potential Pharmacodynamic Interaction Between Pregabalin and Ethanol Administered Orally to Healthy Volunteers (Protocol 1008-079-0). RR 744-00547, September 8, 2000.
31. Bockbrader H, Burger P. Population Pharmacokinetics of Marketed Antiepileptic Drugs Coadministered With Pregabalin in Patients With Partial Seizures. RR-MEMO 764-03729, July 11, 2001.
32. Alvey C, Randinitis E, Posvar E. A Study to Determine the Effects of Pregabalin (CI-1008) on the Pharmacokinetics of an Oral Contraceptive Agent (Ortho-Novum[®] 1/35) Containing Norethindrone Acetate and Ethinyl Estradiol (Protocol 1008-075). RR 744-00484, July 26, 2000.
33. Henck J. Oral Teratology Study in Rats With CI-1008. RR 745-02271, December 16, 1994.
34. Henck J, Morse D, Anderson J. Critical Assessment of Skull Bone Findings Observed in the Oral Teratology Study in Rats With CI-1008. RR 745-03337, September 7, 2000.
35. Morse D. Fetal Skull Development Study of Pregabalin in Wistar Rats. RR 745-03426, October 30, 2001.
36. Morse D. Progression of Skull Development in Rats Following Gestational Exposure to Pregabalin. RR 745-03384, November 1, 2001.
37. Morse D. Postnatal Skull Development Study in Rats With CI-1008. RR 745-03321, January 18, 2001.
38. Petre J. Oral Embryo-Fetal Development Study in Rabbits With CI-1008. RR 745-02285, January 12, 1995.
39. Windsor B, Radulovic L. Plasma and Milk CI-1008 Concentrations in Lactating Rats Following Repeated Gavage Administration of 0, 50, 100, 250, 1250, or 2500 mg/kg/day CI-1008 (Ann Arbor Toxicology Study 1962). RR-MEMO 764-02291, August 23, 1995.
40. Carter C, de Meynard C, Mathe H. An Investigation Into the Effects of Pregabalin (CI-1008), Alprazolam, and Placebo on Cognitive and Psychomotor Function, Car Driving Ability, and Various Aspects of Sleep in Healthy Volunteers (Protocol 1008-097). RR-MEMO 720-30035, April 2, 2001.



41. Sunman-Chauhan N, Webdale L, Hill D, Woodruff, G. Characterization of [³H]-gabapentin Binding to a Novel Site in Rat Brain: Homogenate Binding Studies. *Eur J Pharmacol* 1993; 244:293-301.
42. Brown J, Dissanayake V, Briggs A, Milic M, Gee N. Isolation of the [³H]gabapentin-binding protein/alpha 2 delta Ca₂₊ channel subunit from porcine brain: Development of a radioligand binding assay for alpha 2 delta subunits using [³H]leucine. *Anal Biochem* 1998; 255:236-43.
43. Gee N, Brown J, Dissanayake V, Offord J, Thurlow R, Woodruff G. The novel anticonvulsive drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. *J Biol Chem* 1996; 271:5768-76.
44. Bockbrader H, Burger P, Corrigan B. Population Pharmacokinetics of Pregabalin in Healthy Volunteers and Patients With Partial Seizures. RR 764-03298, August 9, 2001.
45. Bockbrader H, Burger P, Corrigan B. Population Pharmacokinetics of Pregabalin in Healthy Volunteers, Patients With Partial Seizures, and Patients With Various Chronic Pain Disorders. RR 764-03771, August 2, 2001.
46. Bockbrader H. Calculated Mean Pregabalin Pharmacokinetic Parameter Values in Healthy Volunteers Following Single-and Multiple-Dose Administration. RR-MEMO 754-00004, September 27, 2001.
47. McNally W, Feng R, DeHart P, Means S. [¹⁴C]CI-1008 Tissue Distribution in Male Mice Following a Single 10-mg/kg Oral Dose. RR 764-03718, August 24, 2000.
48. McNally W, DeHart P, Radulovic L. Distribution of [¹⁴C]CI-1008 Following Single Oral Dose to Male and Female Cynomolgus Monkeys. RR 764-02352, June 8, 1995.
49. McNally W, DeHart P, Radulovic L. Distribution of [¹⁴C]CI-1008 in Tissues of Male and Female Rats Following Single Oral Dose. RR 764-02227, November 14, 1994.
50. Taylor C, Vartanian M, Welty D, Busch J, Radulovic L. Time Course of Prevention of Maximal Electroshock Seizures in Rats by S (+)-3-isobutyl GABA (CI-1008) and Gabapentin (CI-945) Compared to Concentrations of Radiolabeled Drug in Brain Tissue and Blood Plasma. RR 740-03225, October 14, 1994.
51. Schuh J. Exploratory Oral Dose Range Finding Toxicity Study of CI-1008 in Rats. RR 250-01702, October 30, 2001.
52. Gragtmans N. Four-Week Daily Repeated Dose Oral Toxicity Study of CI-1008 in Rats. RR 250-01722, April 12, 1995.
53. Wojcinski Z. Four-Week Oral Toxicity Study of CI-1008 in Rats. RR 250-01730, June 8, 1995.
54. Pilcher G. 52-Week Oral Toxicity Study of CI-1008 in Male and Female Wistar Rats: 13-Week Interim Report. RR 745-02570, November 13, 1996.
55. Pilcher G. 52-Week Oral Toxicity Study of CI-1008 in Male and Female Wistar Rats. RR 745-02683, August 13, 2001.



56. MacDonald J. Exploratory Oral Rising-Dose Study of PD 144723 in Cynomolgus Monkeys. RR 745-02116, November 8, 1993.
57. Gragtmans N. Oral Dose Range-Finding Toxicity Study of CI-1008 in Cynomolgus Monkeys. RR 250-01713, September 29, 1994.
58. Walker R. Oral Toxicity Study of CI-1008 in Cynomolgus Monkeys. RR 250-01720, November 14, 1994.
59. Ulloa H. 4-Day Oral Toxicokinetic Study of CI-1008 in Cynomolgus Monkeys. RR 745-02268, October 11, 1994.
60. Ulloa H. 4-Week Oral Toxicity Study of CI-1008 in Cynomolgus Monkeys. RR 745-02329, October 6, 1995.
61. Ulloa H. 13- Week Oral Toxicity Study of CI-1008 in Cynomolgus Monkeys. RR 745-02559, December 12, 1996.
62. Ulloa H. Chronic Oral Toxicity Study of CI-1008 in Cynomolgus Monkeys. RR 745-02646, July 21, 1997.
63. Petrere J. Oral Embryo-Fetal Development Study in Mice With CI-1008. RR 745-02273, November 1, 1994.
64. Henck J. Oral Pre- and Postnatal Development Study in Rats With CI-1008. RR 745-02628, April 17, 1998.
65. Henck J. Investigative Study in Rats With CI-1008 Relating Developmental Toxicity to Stage of Exposure. RR 745-02656, December 18, 1997.
66. Bulera S. Bacterial Mutagenicity Assay of CI-1008 Using B6C3F1 and CD-1 Mouse Metabolic Activating Systems. RR 745-03418, November 20, 2002.
67. Kropko M. Standard Ames Bacterial Mutagenicity Assay of PD 144723. RR 745-02035, May 27, 1993.
68. Bulera S. Bacterial Mutagenicity Assay of CI-1008. RR 745-03320, January 19, 2001.
69. Wold S. Mutagenicity Test With CI-1008 in Escherichia Coli WP2uvrA. RR 745-03203, April 27, 2000.
70. Kropko M. *In Vitro* Mutation Assay of CI-1008 in Chinese Hamster Ovary Cells. RR 745-02308, March 22, 1995.
71. Ciaravino V. *In Vitro* Structural Chromosome Aberration Assay of CI-1008 in Chinese Hamster Ovary Cells. RR 745-02393, June 24, 1996.
72. Bulera S. Unscheduled DNA Synthesis Assay of Pregabalin in Female B6C3F1 and CD-1 Mice. RR 745-03455, November 1, 2001.



73. Monteith D. Unscheduled DNA Synthesis in Hepatocytes from Rats Treated With CI-1008. RR 745- 02209, June 27, 1994.
74. Bulera S. Micronucleus Study of CI-1008 in B6C3F1 and CD-1 Mice. RR 745-03387, November 1, 2001.
75. Krishna G. Rat Micronucleus Study of CI-1008. RR 745-02374, June 24, 1996.
76. Henck J (Parke-Davis Reviewer). 2-Year Dietary Oncogenicity Study in Rats With CI-1008. RR 745-03274, May 26, 2000.
77. Criswell K. Retrospective Evaluation of Bone Marrow Megakaryocytes from B6C3F1 Mice (AA 2236) and Wistar Rats (AA2235) Treated With CI-1008 for 2 Years. RR-MEMO 745-03456, November 2, 2001.
78. Dethloff L. 4-Week Oral Toxicokinetic Study of CI-1008 in Male and Female Wistar Rats (Ann Arbor Study 2581). RR-MEMO 745-03238, August 10, 2000.
79. Graziano M (Parke-Davis Reviewer). 2-Year Dietary Oncogenicity Study in Mice With CI-1008. RR 745-03275, May 26, 2000.
80. Metz A. Retrospective Histopathologic Evaluation of Nonneoplastic Findings in Selected Tissues From B6C3F1 Mice Treated With CI-1008 for 2 Years. RR-MEMO 745-03454, November 1, 2001.
81. Criswell K. Retrospective Evaluation of Bone Marrow Megakaryocytes From B6C3F1 Mice (AA2236) and Wistar Rats (AA2235) Treated With CI-1008 for 2 Years. RR-MEMO 745-03456, November 2, 2001.
82. Dethloff L. 4-Week Oral Toxicokinetic Study of CI-1008 in Male and Female B6C3F1 Mice. RR 745-03239, August 8, 2000.
83. Criswell K. Retrospective Evaluation of Peripheral Blood Morphology in B6C3F1 and CD-1 Mice Treated With Pregabalin for 2 Years. RR-MEMO 745-03714, January 13, 2003.
84. Petrere J. Acute Oral Toxicity Study of CI-1008 in 7-Day-Old and 21-Day-Old Male and Female Wistar Rats. RR 745-03151, October 29, 1999.
85. Petrere J. Developmental Neurotoxicity Study of CI-1008 in Juvenile Male and Female Wistar Rats. RR 745-03323, August 4, 2001.
86. Petrere J. 7-Week Oral Toxicity Study of CI-1008 in 7-Day-Old Male and Female Wistar Rats. RR 745-03294, May 21, 2001.
87. Petrere J. Reproductive Toxicity Study of CI-1008 in Juvenile Male and Female Wistar Rats. RR 745-03267, April 25, 2001.
88. Petrere J. Repeat Reproductive Toxicity Study of CI-1008 in Juvenile Female Wistar Rats. RR 745-03471, April 15, 2002.



89. Petrere J. Oral Toxicokinetic Study of CI-1008 in Juvenile (7-Day-Old) Male and Female Wistar Rats. RR 745-03375, June 14, 2001.
90. Petrere J. Oral Toxicokinetic Study of CI-1008 in Adult Male and Female Wistar Rats. RR 745--03376, June 14, 2001.
91. Stanco S. Periodic Safety Update Report Pregabalin, 07 July 2004 through 06 January 2005. Pfizer, Inc. 25 January 2005.
92. Mohan JD. Pregabalin swelling of face and tongue. Pfizer, Inc. July 18, 2005.
93. Mohan J. Pregabalin and Headache, Pfizer, Inc. 23 August 2005.
94. Mohan J. Pregabalin and Nausea, Pfizer, Inc. 23 August 2005.
95. Magliano S and Long C. Periodic Safety Update Report Pregabalin, 01 August 2005 through 31 January 2006, Pfizer Inc., 27 March 2006.
96. Shah J. Congestive Heart Failure in Pregabalin Patients With or Without Cardiac Disease. Pfizer Inc., 29 August 2006.
97. Long C. Postmarketing Review of Pregabalin and Reports of Allergic Conditions. Pfizer Inc., 20 October 2006.
98. Gupta A. Pregabalin Cases Reporting Diarrhea-Events. Pfizer Inc., 03 March 2006.
99. Long C. Postmarketing Review of Pregabalin and Reports of Pruritus. Pfizer Inc., 12 October 2006.
100. Study No. 04-2777-01 Oral Toxicity Study of C1-1008 (Pregabalin) In Juvenile Wistar Rats. Pfizer Inc., November 2005.
101. Pfizer Inc., Module 2.5 Clinical Overview: Pregabalin for the Treatment of Generalized Anxiety Disorder, dated 17 Jun 2005.
102. Pfizer Inc., Module 2.5 Clinical Overview: Lyrica (Pregabalin); Response to Rapporteurs' Final Assessment Report (dated 21 December 2006) Concerning the Lyrica Periodic Safety Update Report #4 (PSUR submitted 2 October 2006).
103. Bromleigh C. Cumulative Review of Pregabalin Cases Reporting Loss of Consciousness. Pfizer Inc. 23 April 2007.
104. Bromleigh C. Cumulative Review of Pregabalin Cases Reporting Mental Impairment. Pfizer Inc. 30 March 2007.
105. Pfizer Inc., Module 2.5 Clinical Overview: Pregabalin for the Treatment of Fibromyalgia, dated 07 December 2006.
106. Magliano A and Long C. Periodic Safety Update Report Pregabalin, 01 August 2006 through 31 January 2007, Pfizer Inc, 23 March 2007.



107. Shah J. A Cumulative Review of Pregabalin Cases Reporting Angioedema and Related terms, Dated 28 November 2007.
108. Module 2.5 Clinical Overview: Type II Variation Application to Support an Additional Indication for the Use of Lyrica in the Treatment of Fibromyalgia in Adults, Pfizer Inc., dated 18 March 2008.
109. Module 2.5 Clinical Overview: Type II Variation (Ocular Events And Angioedema), Pfizer Inc. 07 December 2007.
110. Pfizer Inc. Periodic Safety Update Report Pregabalin, 01 February 2008 through 31 July 2008, Pfizer Inc, dated 26 September 2008.
111. Module 2.5 Clinical Overview: Analysis of Treatment-Related Adverse Events in Placebo-Controlled Pregabalin Studies, Pfizer, Inc. dated 30 September 2008.
112. Discontinuations Due to Treatment Emergent Treatment Related Adverse Events Approved Indications and Fibromyalgia Studies. Dated 13 February 2008.
113. Pfizer Inc. Periodic Safety Update Report, 01 February 2009 through 31 July 2009, dated 22 September 2009.
114. Module 2.5 Clinical Overview: CDS update (Discontinuation-Related Anxiety, GI motility, Malaise), Pfizer Inc. 15 October 2009.
115. Module 2.5 Clinical Overview: CDS update (Discontinuation-Related Hyperhidrosis), Pfizer Inc. 06 April 2010.
116. Bauer C, Nieto-Rostro M, Rahman W, *et al.* The Increased Trafficking of the Calcium Channel Subunit $\alpha_2\delta$ -1 to Presynaptic Terminals in Neuropathic Pain Is Inhibited by the $\alpha_2\delta$ Ligand Pregabalin. *J Neurosci* 2009; 29(13):4082, 4084-4085.
117. Takeuchi Y, Takasu K, Ono H, *et al.* Pregabalin, *S*(+)-3-isobutylgaba, activates the descending noradrenergic system to alleviate neuropathic pain in the mouse partial sciatic nerve ligation model. *Neuropharmacology* 2007; 53:843-844, 846-851.
118. Bee L, Dickenson A. Descending facilitation from the brainstem determines behavioural and neuronal hypersensitivity following nerve injury and efficacy of pregabalin. *Pain* 2008; 140:209-210, 216-219, 221-222.
119. Rahman W, Bauer C, Bannister K, *et al.* Descending serotonergic facilitation and the antinociceptive effects of pregabalin in a rat model of osteoarthritic pain. *Mol Pain* 2009; 5:46, 49, 51-57.
120. Module 2.5 Clinical Overview: Changes to the Pregabalin Core Data Sheet: Addition of Gynaecomastia and Breast Enlargement, Pfizer Inc. 11 May 2011.
121. Pregabalin 2.6.2 Pharmacology Written Summary 2004.
122. Module 2.5 Clinical Overview: Changes to the Pregabalin Core Data Sheet: Addition of Potential Abuse Language, Pfizer Inc. 12 October 2012.



123. Foerg A, Hein J, Volkmar M, *et al.* Efficacy and safety of pregabalin in the treatment of alcohol withdrawal syndrome: A randomized, placebo-controlled trial. *Alcohol Alcoholism* 2012;47(2): 149-55.
124. Skopp G, Zimmer G. Pregabalin—a drug with abuse potential? *Arch Kriminol* 2012;229(1-2): 44-54.
125. Zacny JP, Paice JA, Coalson DW. Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. *Pharmacol Biochem Behav* 2012; 100(3): 560-5.
126. Bjaanes TK, Fossan KO, Schjott J, *et al.* Prevalence of pregabalin in urine samples from patients treated for substance-dependency. *Basic Clin Pharmacol Toxicol. Proceedings of the 10th Congress of the European Association for Clinical Pharmacology and Therapeutics (26-29 June 2011 Budapest Hungary).* 2011; 109: 79.
127. Oulis P, Nakkas G, Masdrakis VG. Pregabalin in zolpidem dependence and withdrawal. *Clin Neuropharmacol* 2011; 34(2): 90-1.
128. Rubio G, Bobes J, Cervera G, *et al.* Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use. *Eur Addict Res* 2011; 17(5): 262-70.
129. Schifano F, D’Offizi S, Piccione M, *et al.* Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. *Psychother Psychosom* 2011; 80(2): 118-22.
130. Yargic I, Ozdemiroglu FA. Pregabalin abuse: A case report. *Klin Psikofarmakol B.* 2011; 21: 64-6.
131. Di Nicola M, Martinotti G, Tedeschi D, *et al.* Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. *Hum Psychopharm* 2010; 25(3): 268-75.
132. Filipetto FA, Zipp CP, Coren JS. Potential for pregabalin abuse or diversion after past drug-seeking behavior. *J Am Osteopath Assoc* 2010; 110(10): 605-7.
133. Grosshans M, Mutschler J, Hermann D, *et al.* Dependence and withdrawal: A case report. *Am J Psychiat* 2010; 167(7): 869.
134. Martinotti G, Di Nocola M, Frustaci A, *et al.* Pregabalin, tiapride, and lorazepam in alcohol withdrawal syndrome: A multi-centre, randomized, single-blind comparison trial. *Addiction* 2010; 105(2): 288-99.
135. Martinotti G, Di Nocola M, Redeschi D, *et al.* Pregabalin versus naltrexone in alcohol dependence: A randomized, double-blind, comparison trial. *J Psychopharmacol* 2010; 24(9): 1367-74.
136. Reedy SJD, Schwartz MD. A case series of recreational pregabalin overdose resulting in generalized seizures. *Clin Toxicol. Proceedings of the 2010 North American Congress of Clinical Toxicology (7-12 Oct 2010, Denver, CO).* 2010; 48 (6): 616-7.



137. Schwan S, Sundstrom A, Stjernberg E, *et al.* A signal for an abuse liability for pregabalin: Results from the Swedish spontaneous adverse drug reaction reporting system. *Eur J Clin Pharmacol* 2010; 66(9): 947-53.
138. Sjoberg G, Feychting K. Pregabalin overdose in adults and adolescents: Experience in Sweden. *Clin Toxicol Proceedings of the International Congress of the European Association of Poisons Centres and Clinical Toxicologists* (11-14 May 2010, Bordeaux, France). 2010; 48 (3): 282.
139. Martinotti G, Di Nicola M, Tedeschi D, *et al.* Efficacy and safety of pregabalin in alcohol dependence. *Adv Ther* 2008; 25(6): 608.
140. Oulis P, Masdrakis VG, Karakatsanis NA, *et al.* Pregabalin in the discontinuation of long-term benzodiazepine use: A case series. *Int Clin Psychopharm* 2008; 23(2): 110-12.
141. 2.5 Clinical Overview Frequency Assessment for the Core Data Sheet, September 2013.
142. 2.5 Clinical Overview Pregabalin Core Data Sheet Change: Revision of Abuse Warning Text, January 2014.
143. 2.5 Clinical Overview Changes to the Pregabalin Core Data Sheet for Lactation Text, Sections 4.6 and 5.2, April 2014.
144. 2.5 Clinical Overview Changes to the Pregabalin Core Data Sheet for Seizures Text, Section 4.9, May 2016.
145. 2.5 Clinical Overview Changes to the Pregabalin Core Data Sheet for Fatal Events Text, Section 4.5, January 2019.
146. 2.5 Clinical Overview Changes to the Pregabalin Core Data Sheet for Concomitant Use with Opioids Text, Section 4.4, June 2019.
147. 2.5 Clinical Overview Changes to the Pregabalin Core Data Sheet for Fertility, Pregnancy and Lactation, Section 4.6, April 2021.
148. 2.5 Clinical Overview Changes to the Pregabalin Core Data Sheet for Special warnings and precautions for use, Section 4.4 and Fertility, Pregnancy and Lactation, Section 4.6, September 2021.
149. 2.5 Clinical Overview, To Support Updates to Section 4.4. Special Warnings and Precautions for Use, December 2021.
150. 2.5 Clinical Overview, To Support Updates to Section 4.8. Undesirable Effects, December 2021.